Virginiamycin Complex

• UNSPSC Description:

  Virginiamycin complex contains two streptogramin antibiotics, virginiamycin M1 and virginiamycin S1 produced by S. virginiae. As a complex, the two antibiotics act synergistically to irreversibly inhibit protein synthesis in bacteria[1].

• Target Antigen:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/virginiamycin-complex.html

• Purity:

  94.28

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1CCN([C@@]([H])(C1)C(N[C@H](C(O[C@@H]([C@@H](C(N[C@@H](C(N2CCC3)=O)CC)=O)NC(C4=NC=CC=C4O)=O)C)=O)C5=CC=CC=C5)=O)C([C@H](CC6=CC=CC=C6)N(C([C@@]23[H])=O)C)=O.O=C(NC/C=C\C(C)=C\[C@H](C7)O)/C=C/[C@H]([C@H](OC(C8=CCCN8C(C9=COC(CC7=O)=N9)=O)=O)C(C)C)C

• Molecular Weight:

  1349.48

• References & Citations:

  [1]Parfait R, Cocito C. Lasting damage to bacterial ribosomes by reversibly bound virginiamycin M. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5492-6.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  11006-76-1